Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 study
Kung, E.; Deo, R.; Choudhary, M. C.; Chew, K. W.; Evering, T. H.; Ignacio, R. B.; Ignacio, R. B.; Jagannathan, P.; Flynn, J. P.; Regan, J.; Moser, C.; Giganti, M. J.; Hughes, M. D.; Ritz, J.; Javan, A. C.; Greninger, A. L.; Singh, U.; Fischer, W.; Daar, E. S.; Wohl, D. A.; Eron, J. J.; Currier, J. S.; Coombs, R. W.; Smith, D. M.; Li, J. Z.
Show abstract
To evaluate the impact of sex on acute SARS-CoV-2 infection, 668 participants from the ACTIV-2/A5401 study were followed over a 28-day period. A primary analysis was performed on the 469 participants who had quantifiable viral loads at baseline. Male and female participants had comparable nasal SARS-CoV-2 RNA levels at study entry and throughout follow-up. However, sex-specific differences in viral shedding emerged when stratified by duration of symptoms. In the first three days from symptom onset, female participants exhibited higher nasal SARS-CoV-2 RNA levels than males, but lower viral RNA levels thereafter. The higher viral RNA levels in females during the earliest phase of acute COVID-19 was seen even after adjusting for age, race and region of enrollment. Female participants also tended to have higher symptom scores across days since symptom onset but no significant correlation was observed between nasal SARS-CoV-2 RNA levels and symptom score regardless of sex. These findings highlight the impact of sex on both viral shedding and symptom dynamics and underscore the importance of considering time since symptom onset when evaluating respiratory virus antiviral therapies in clinical trials.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Virologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for COVID-19 93%
- Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial 93%
- The New Normal: Delayed Peak SARS-CoV-2 Viral Loads Relative to Symptom Onset and Implications for COVID-19 Testing Programs 93%
Similar papers in this journal
- CHARM: COVID-19 Health Action Response for Marines - association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test 92%
- The COVID HOME study research protocol: Prospective cohort study of non-hospitalised COVID-19 patients 92%
- Study protocol for the Innovative Support for Patients with SARS-COV-2 Infections Registry (INSPIRE): a longitudinal study of the medium and long-term sequelae of SARS-CoV-2 infection 92%
Similar papers in this journal
- SARS-CoV-2 virus dynamics in recently infected people – data from a household transmission study 93%
- Markers of immune activation and inflammation in individuals with post-acute sequelae of SARS-CoV-2 infection 92%
- Screening for high amounts of SARS-CoV-2 identifies pre-symptomatic subjects among healthy healthcare workers 92%
Similar papers in this journal
- Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19, A double-blind, randomized placebo-controlled trial. 93%
- A cohort study of Post COVID-19 Condition across the Beta, Delta and Omicron waves in South Africa: 6-month follow up of hospitalised and non-hospitalised participants 91%
- Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial (HERO-HCQ) 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.